Business Context and Reporting Period
This Form 6-K filing by Bionomics Limited (not Neuphoria Therapeutics Inc.) covers the period ended June 30, 2022, with the report released on July 29, 2022. The filing serves to furnish the Company's Appendix 4C Quarterly Cashflow Report, as required by Australian Securities Exchange (ASX) regulations, to the U.S. Securities and Exchange Commission.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document acts as a cover sheet referencing an attached exhibit (Exhibit 99.1) containing the actual financial data, which is not included in the provided text.
Material Changes
No material changes versus the prior comparable period are described in the filing text, as the document does not contain comparative financial data.
Guidance, Outlook, and Risks
The filing text contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It strictly references the submission of the quarterly cashflow report to the ASX.
Investor Verification Checklist
- Verify the actual financial figures by reviewing Exhibit 99.1 (Quarterly Report for the Period Ended June 2022), which is referenced but not included in this text.
- Confirm the registrant is Bionomics Limited, an Australian entity, rather than Neuphoria Therapeutics Inc.
- Check the ASX website for the full Appendix 4C report to analyze cash burn and liquidity status.